ABSORB III Randomized Controlled Trial (RCT)

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2008 participants.

Also called NCT01751906

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 2,008 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01751906
Other papers using this trial's data
  • 3-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Coronary Scaffolds: The ABSORB III Trial Journal of the American College of Cardiology, 2017-12-12 DOI, PubMed 29100702
  • Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial JACC. Cardiovascular interventions, 2017-04-24 DOI, PubMed 28427593

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01751906. Randomized; single masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2016-09 (actual). Results posted on 2018-02-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ABSORB III Randomized Controlled Trial (RCT)
Acronym
ABSORB-III
Condition
Coronary Artery Stenosis
Condition
Coronary Disease
Condition
Coronary Stenosis
Intervention (Device)
Absorb BVS
Intervention (Device)
XIENCE
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct01751906
Content hash
76b7850b580a3456c040e73e87bfb0e4fc02392e9599898698a03e06e7a7f821